Immuno-oncology therapies which
harness the body’s own defences to fight off tumours are widely acknowledged as
the new frontier in cancer treatment. However, these therapies come with a very
high price tag and currently only a few of these drugs have actually reached
the market including Opdivo, Keytruda and Yervoy. In this video Director Sue
Marett discusses the opportunities and challenges for new immuno-oncology
therapies and outlines what these mean for pharma market research.
In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital. Research Partnership
Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division. Research Partnership
Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment of Serious Allergic Reactions. Research Partnership
Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive. Research Partnership
We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards. Research Partnership
Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device. Research Partnership